# **Congress President**

R.M. Lemoli

### **Scientific Committee**

M. Cea (Chair)

A. Cagnetta

M. Garibotto

M. Olivieri

E. Catini

M. Gallo

A. Laserra

### **GENERAL INFORMATION**

DATE 20/21 November 2023

#### **VENUE**

**NH Marina Collection** Molo Ponte Calvi, 5 16124 Genova, Italy

#### **CONFERENCE LANGUAGE**

English

### REGISTRATION

Congress registration is free and pre-registration online is mandatory due to limited seat availability. Registrants will be admitted based on the "first come-first served" rule (date of registration will be considered), until the maximum number allowed is reached. This event will be only in-presence Online pre-registrations should be submitted online before October 30, 2023 at

# www.eventuallyevents.it

The attendance is guaranteed only to preregistered participants.

### **CME CREDITS Continuing Medical Education**

(Valid for Italian CME only) **Event:** Residential 1038-389794 ID Event:

N° of credits: 8,4 CME Italian Credits

Professions: Medical Doctors (All disciplines)

**Biologists** 

To earn CME credits you must:

- Participate in at least 90% of the learning
- Give correct answers to at least 75% of the questions on the CME questionnaire. The test will be available at the end of the meeting.
- Fill out the perceived-quality form & survey
- Sign the "sign-in sheet" at the start and end of the Congress

Provider



Staff P&P Provider ECM N° 1038

### **ORGANIZING SECRETARIAT**



Phone +39 327 3752740 Email info@eventuallyevents.it www.eventuallyevents.it

# **2023 Multiple Myeloma update:** from bench to bedside



# Nh Marina Hotel, Genoa, Italy **20-21 November 2023**

### Monday - November 20th, 2023

08:30 Registration

### **OPENING SESSION**

09:00 Welcome address R.M. Lemoli, P. Ruggeri, A. Uccelli

09:30 Opening lecture: Changing landscape in the diagnosis and treatment of Multiple Myeloma K.C. Anderson Introducing R.M. Lemoli

# GENETICS AND EPIGENETICS OF MULTIPLE MYELOMA Chairs: *M. Cea, N. Giuliani*

10:20 Functional impact of genomic complexity of the transcriptome of Multiple Myeloma N. Bolli

10:45 miRNA and IncRNA of bone marrow microenvironment as support for Myeloma plasma cells A. Neri

11:10 Epigenetic architecture in Multiple Myeloma A. Roccaro

11:35 Drugging Transcription factors in Multiple Myeloma M.T. Fulciniti

12:00 Current Risk Stratification M. D'Agostino

12:25 Clonal Hematopoiesis as a biomarker in Multiple Myeloma C. Terragna

14:00 Keynote Lecture: Cellular Therapy for Multiple Myeloma: What's Now and What's Next N.C. Munshi Introducing M. Cea

### BIOLOGY OF DISEASE PROGRESSION AND ORGAN DAMAGE IN MULTIPLE MYELOMA

Chairs: M. Boccadoro, A. Neri

14:50 Circulating tumor cells and homing to predict Myeloma progression R.Ria

15:15 Molecular pathways governing the pathogenesis of Myeloma bone disease N.Giuliani

15:40 Emerging therapeutic targets in Multiple Myeloma M.Cea

16:20 Novel strategies for the management of AL Amyloidosis G. Palladini

16:45 Management of Monoclonal Gammopathy of Clinical Significance A. Cagnetta 17:10 The Consultant's Guide to Smouldering Multiple Myeloma E. Zamagni

17:35 Closing - M. Cea, R. M. Lemoli

## Tuesday – November 21st, 2023

### **MULTIPLE MYELOMA CLINICAL UPDATES**

Chairs: M. Cavo, M. Gobbi

09:00 Frontline therapy for newly diagnosed young patients R. Mina

09:25 Newly diagnosed elderly and very elderly Myeloma patients S. Bringhen

09:50 Optimal Therapy for High Risk Myeloma (newly diagnosed and relapsed) P. Tacchetti

10:15 Coffee break

### **CLINICAL MANAGEMENT OF MULTIPLE MYELOMA PATIENTS**

Chairs: M. Cavo, M. Gobbi

10:30 Clinical or biochemical progression of Myeloma: when patients need treatment *F. Di Raimondo* 10:55 Lenalidomide-based triplet regimens in first relapsed Multiple Myeloma patients:

real-world evidence S. Mangiacavalli

11:20 The choice of therapy at first relapse: focus on Len-refractory Patients A. La Rocca 11:45 Disease monitoring: how to use MRD in clincal practice S. Oliva

### HARNESSING IMMUNITY FOR MM TREATMENT

Chairs: E. Angelucci, R.M. Lemoli

12:10 Understanding mechanisms of resistance to immunotherapies Integrating cellular therapy in the treatment P. Rodriguez Otero

12:35 Optimizing Monoclonal Antibodies therapy for Multiple Myeloma:

new targets and new agents M. Cavo

13.00 The immunosuppressive microenvironment of Multiple Myeloma M. Massaia 13:25 CAR T cells and bispecific antibodies in MM: how to tailor immunotherapy? B. Bruno

13:50 Closing Remarks - M. Cea, R. M. Lemoli

14:00 CME Test

Closing of the congress